The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.

CHMP Adopts Positive Opinion for Aflibercept, Pegfilgrastim Biosimilars:  On January 30, 2025, the European Medicines Agency (EMA) Committee ...

The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...

Biocon plans to list its biosimilars business by March 2026 and aims for a double-digit market share in the U.S. for five new ...

Dr. Reddy's (RDY) partners with Shanghai Henlius Biotech to develop and market biosimilar versions of J&J's (JNJ) multiple ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

The U.S. Food and Drug Administration (FDA) has accepted for review Biologics License Applications (BLA) for AVT05, ...

By Rishika Sadam HYDERABAD (Reuters) -Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by March 2026 and aims for double-digit share in its core U.S. market for its ...

The new biosimilar, Celltrion’s Avtozma, was approved in both IV and subcutaneous forms to treat inflammatory conditions such as arthritis.